Frank J Carrillo-Rodes

Dr. Frank J Carrillo-Rodes


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
JÁJosé Alberto Álvarez-Cuesta
José Alberto Álvarez-Cuesta
Camilo Mora-BatistaCamilo Mora-Batista
Camilo Mora-Batista
RAMON REYES CARRETORAMON REYES CARRETO
RAMON REYES CARRETO
FCFrank J Carrillo-Rodes
Frank J Carrillo-Rodes
Sergio J. Torralbas FitzSergio J. Torralbas Fitz
Sergio J. Torralbas Fitz
CVCruz Vargas-De-León
Cruz Vargas-De-León
(1) Background: Spinocerebellar ataxias (SCA) is a term that refers to a group of hereditary ataxias, which are neurological diseases characterized by degeneration of the cells that constitute the cerebellum. Studies suggest that magnetic resonance imaging (MRI) supports diagnoses of ataxias, and linear measurements of the aneteroposterior diameter of the midbrain (ADM) have been investigated using MRI. These measurements correspond to studies in spinocerebellar ataxia type 2 (SCA2) patients and in healthy subjects. Our goal was to obtain the cut-off value for ADM atrophy in SCA2 patients. (2) Methods: This study evaluated 99 participants (66 SCA2 patients and 33 healthy controls). The sample was divided into estimations (80%) and validation (20%) samples. Using the estimation sample, we fitted a logistic model using the ADM and obtained the cut-off value through the inverse of regression. (3) Results: The optimal cut-off value of ADM was found to be 18.21 mm. The area under the curve (AUC) of the atrophy risk score was 0.957 (95% CI: 0.895–0.991). Using this cut-off on the validation sample, we found a sensitivity of 100.00% (95% CI: 76.84%–100.00%) and a specificity of 85.71% (95% CI: 42.13%–99.64%). (4) Conclusions: We obtained a cut-off value that has an excellent discriminatory capacity to identify SCA2 patients.

10 June 2026 in The Cerebellum
Verified
Journal Article
Closed access
RTReidenis Torres-Vega
Reidenis Torres-Vega
RLRoberto Rodriguez Labrada
Roberto Rodriguez Labrada
YGYasmany González-Garcés
Yasmany González-Garcés
JMJacqueline Medrano-Montero
Jacqueline Medrano-Montero
IVIliana Feria Velázquez
Iliana Feria Velázquez
LVLuis Velazquez-Perez
Luis Velazquez-Perez

24 June 2026 in Tomography
Verified
Journal Article
Open access
PDF file
Camilo Mora-BatistaCamilo Mora-Batista
Camilo Mora-Batista
CVCruz Vargas-De-León
Cruz Vargas-De-León
RAMON REYES CARRETORAMON REYES CARRETO
RAMON REYES CARRETO
FCFrank J Carrillo-Rodes
Frank J Carrillo-Rodes
JÁJosé Alberto Álvarez-Cuesta
José Alberto Álvarez-Cuesta
Background: Spinocerebellar ataxia type 2 (SCA2) is an inherited neurodegenerative disorder characterized by progressive cerebellar degeneration. One difficulty in treating this disease lies in identifying preclinical carriers: individuals who carry the pathogenic ATXN2 mutation but remain asymptomatic with respect to motor manifestations. Though magnetic resonance imaging (MRI) has proven valuable in supporting the diagnosis of ataxia, traditional univariate approaches using linear measurements have shown limited ability to capture the complex anatomical changes that occur across the disease spectrum, particularly during the preclinical phase. Methods: This study employed a comprehensive multivariate approach to improve the classification of individuals across the SCA2 spectrum. We developed a multinomial logistic regression model incorporating multiple linear measurements derived from magnetic resonance imaging to discriminate between healthy controls (n = 72), preclinical carriers (n = 17), and patients with manifest SCA2 (n = 61). To mitigate inherent class imbalance, particularly in the smaller preclinical subgroup, we implemented the Synthetic Minority Over-sampling Technique (SMOTE), generating a balanced dataset that enhances the model’s ability to discern the distinctive anatomical features. This was compared to the model applied to the unbalanced data. An improvement was observed when applying SMOTE. Results: The multivariate model demonstrated discriminatory performance, achieving an overall accuracy of 80.7%. The ability to identify healthy controls (AUC: 0.96), preclinical individuals (AUC: 0.75), and clinical individuals (AUC: 95%). This represents an advance over previous univariate approaches, which have had difficulty capturing the neurodegenerative changes characteristic of the preclinical stage. Conclusions: By integrating multiple neuroimaging biomarkers into a multivariable model, this study provides a tool for early identification of preclinical SCA2 carriers. The ability to accurately classify these individuals opens an opportunity for early therapeutic intervention before irreversible neurological deterioration occurs. This approach shows promise for optimizing clinical trial design and personalized care in SCA2.